Core Viewpoint - The controlling shareholder of Liansheng Chemical, Liansheng Group, and its action-in-concert partner, Taizhou Gaosheng Investment Partnership, plan to reduce their shareholding in the company through centralized bidding and block trading, with a total reduction not exceeding 3% of the company's total shares [1][2]. Group 1: Shareholding Reduction Plan - Liansheng Group holds 57,000,000 shares (52.78% of total shares), while Taizhou Gaosheng holds 5,000,000 shares (4.63% of total shares) [1]. - The planned reduction involves a maximum of 3,240,000 shares (3% of total shares) over a period of three months, starting 15 trading days after the announcement [1]. - The reduction will be subject to limits: no more than 1% of total shares can be sold through centralized bidding within any 90-day period, and no more than 2% through block trading [1]. Group 2: Financial Implications - Based on the closing price of 30.97 yuan, the total cash to be realized from the share reduction is approximately 100 million yuan [2]. - Liansheng Chemical has not experienced a decline in share price below its offering price, and its cumulative cash dividends over the past three years have not been less than 30% of the average annual net profit [2]. - The share reduction is characterized as a normal behavior of shareholders and is not expected to significantly impact the company's governance structure, ownership structure, or future operations [2]. Group 3: Company Background - Liansheng Chemical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on April 19, 2022, with an initial public offering of 27 million shares at a price of 29.67 yuan per share [2]. - The company raised a total of 801 million yuan from its IPO, with a net amount of 727 million yuan after deducting issuance costs [3]. - The funds raised are intended for projects including the renovation of a 526,000-ton/year electronic and specialty chemicals project and new projects for ultra-pure electronic chemicals and biodegradable new materials [3].
联盛化学控股股东方拟减持套现1亿元 2022年上市募8亿